Business
House Approves Spending Bill with Amendments for Veteran Medical Cannabis Treatments
Medical cannabis for veterans and psychedelic substance research amendments were recently approved in a House spending bill.
On July 26, the U.S. House of Representatives approved amendments and added a large spending bill. Among those amendments was an addition that would permit doctors from the U.S. Department of Veterans Affairs to recommend medical cannabis for veterans, as well as allow research to be conducted for other psychedelic substances with medical benefits.
The amendment was one of many proposed to be added to the 2024 Military Construction, Veterans Affairs, and Related Agencies appropriations bill, also referred to as HR-4366, which “…prevents the VA [Veterans Affairs] from interfering with a veteran’s ability to participate in a legal state medical cannabis program, deny service to such a veteran, or limit health care providers’ ability to make appropriate recommendations of this treatment option for veterans.” The measure was introduced by Rep. Brian Mast, Rep. Earl Blumenauer, Rep. Dave Joyce, and Rep. Barbara Lee.
According to Mast, the measure is a necessity for military veterans. “I rise in support of a bipartisan amendment and it’s to do something simple—give veterans access to every possible tool when it comes to the wounds of war of which I am innately familiar,” Mast said. “The amendment is quite simple. It allows VA doctors in states with legal medical cannabis programs to discuss cannabis as a treatment option with their patients.” He explained that he has personal friends, from rangers to green berets, who have found relief from both mental and physical wounds by using medical cannabis.
Blumenauer also stated that it is Congress’s responsibility to pass legislation that allows veterans to use medical cannabis. “These veterans have also shared their fear about what happened if they work with the VA doctors to incorporate their cannabis use into their treatment plans. The VA denies veterans access to this care option by preventing providers from completing forms in compliance with state medical marijuana programs,” Blumenauer said. “This is a shameful disservice to the men and women who put their lives on the line. The VA is forcing veterans to seek care outside the VA or self-medicate. Our veterans are paying the price for Congress’s failure to act.”
Joyce also spoke in favor of the amendment, adding that he is “…proud to join my colleagues in leading this commonsense effort to help our country’s veterans access medical treatment. I’ve seen firsthand the many challenges our nation’s heroes face when they return home,” Joyce said. “We should all be resolved to help expand access to treatments for the medical challenges, both mental and physical, our nation’s veterans experience.”
Opposition was presented by Rep. Debbie Wasserman Schultz and Rep. John Carter, claiming that VA doctors could legally be put at risk for recommending medical cannabis.
The House also recently approved an amendment, introduced by Rep. Lou Correa and Rep. Jack Bergman, to allow research to be conducted for other psychedelic substances. “If psychedelic-assisted therapy can treat a veterans’ PTSD or prevent them from taking their own life, then we owe it to them to take an active role in researching these potentially lifesaving therapies,” said Bergman. “This amendment will unlock potential treatments that have been shown to actually cure PTSD—something current medicine and modern psychology have been unable to do—and give our veterans a chance to live a long, happy life that we all take for granted.”
Correa added that it’s time to “take care of business” and ensure that the VA studies psychedelics and uses those findings to develop a program for veterans. “Veterans have fought for our freedom. It’s time that we continue and step up to fulfill our moral obligation to take care of them as well,” Correa said.
A study published by the University of North Texas and University of Illinois in April found that one in 10 U.S veterans, or approximately 16,000 veterans, have used cannabis within the past year. Another study from the Iraq and Afghanistan Veterans of America found that 83% of the organization’s veterans supported legal medical cannabis access and 55% supported recreational legalization.
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy